Compound to Control Presbyopia Symptoms

Optall Vision

Status and phase: Completed; Phase 1

Conditions: Presbyopia

Treatments: Combination Product: PBO to control presbyopia symptoms

Study type: Interventional

Funder types: Other

Identifiers

NCT05006898

PBOPC01

Details and patient eligibility

About

Low dose compose to control presbyopia symptoms

Full description

A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.

Enrollment: 11 patients

Sex: All

Ages: 40 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy
• Presbyopic
• 40 - 59 years

Exclusion criteria

• Diabetics
• Previous eye surgery
• Previous eye disease
• > 0.50 myopia
• > 1.5 hyperopia or astigmatism

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

11 participants in 3 patient groups

PBO Investigational drug

Experimental group

Description:

Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.

Treatment:

Combination Product: PBO to control presbyopia symptoms

Pilocarpine

Active Comparator group

Description:

Pilocarpine was instilled in the other oye.

Treatment:

Combination Product: PBO to control presbyopia symptoms

Brimonidine

Active Comparator group

Description:

Brimonidine was instilled in the other eye.

Treatment:

Combination Product: PBO to control presbyopia symptoms